PROK

ProKidney Corp. develops cellular therapies for the treatment of chronic kidney disease (CKD). Headquartered in Winston-Salem, North Carolina, the company focuses on regenerative medicine using its proprietary Renal Autologous Cell Therapy (REACT) platform. REACT utilizes a patient's own kidney cells to create a therapeutic product designed to slow or stabilize kidney function decline in individuals with diabetic kidney disease and other forms of CKD. The company's lead investigational product, REACT, undergoes clinical evaluation through multiple trials, including the PROACT program which comprises Phase 3 studies assessing efficacy and safety in patients with Type 2 diabetes and CKD. ProKidney operates manufacturing facilities to support its cell therapy production requirements and maintains research operations across multiple locations. ProKidney emerged as a publicly traded entity in 2022 through a business combination with Social Capital Suvretta Holdings Corp. I, a special purpose acquisition company. The company positions itself within the emerging regenerative medicine sector, specifically targeting a substantial patient population affected by kidney disease. With chronic kidney disease impacting millions globally and treatment options remaining limited beyond dialysis and transplantation, ProKidney pursues regulatory approvals for its cell-based therapeutic approach. The company collaborates with clinical sites internationally to advance its development programs and expand its clinical evidence base for the REACT platform.